Prognostic Significance of Serum Uric Acid in Patients Admitted to the Department of Medicine

被引:33
作者
Wasserman, Asaf
Shnell, Matti
Boursi, Ben
Guzner-Gur, Hanan [1 ]
机构
[1] Tel Aviv Sourasky Med Ctr, Dept Med B, IL-54239 Tel Aviv, Israel
关键词
Uric acid; Biomarker; Prognosis; Mortality; Internal Medicine; CALCIUM-CHANNEL BLOCKER; ALL-CAUSE MORTALITY; HEART-FAILURE; CARDIOVASCULAR-DISEASE; SYSTOLIC HYPERTENSION; ENDOTHELIAL FUNCTION; RENAL-DISEASE; HIGH-RISK; HYPERURICEMIA; COHORT;
D O I
10.1097/MAJ.0b013e3181bbb647
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Hyperuricemia has been linked to proatherogenic processes, including increased oxidative stress and leukocyte activation, and was shown to predict adverse prognosis in heart failure, renal failure, and hypertension. Recently, serum uric acid (SUA) was shown to be in independent predictor of long-term mortality in patients with cardiovascular diseases. However, the prognostic significance of SUA for the short-term outcome of admitted medical patients is unknown. Methods: Initial SUA, together with epidemiological, clinical, and laboratory data, was analyzed for a prospective cohort of 650 consecutive adult patients admitted to the department of internal medicine during a 3-month period. Results: The mean, median, and range of SUA at admission were 6.1 +/- 2.7, 5.6, and 1.2 to 24 mg/dL, respectively. Increased SUA was significantly correlated with age, gender, comorbidities (coronary heart disease, heart failure, hypertension, diabetes, renal failure, and gout), use of diuretics, and current admission for cardiovascular diseases but not with current diagnosis of infection, malignancy, or inflammatory diseases, nor with C-reactive protein. However, SUA significantly correlated with mortality (7.7 versus 6 mg/L, P < 0.025) and was an independent predictor of mortality in a multivariate regression analysis (odds ratio: 1.11; confidence interval: 1.003-1.218; P = 0.04), with a significant difference in mortality between normal SUA (<6 mg/dL) with 5% mortality and high SUA (> 12 mg/dL) with 27% mortality. Conclusions: Initial SUA is an independent predictor of mortality in admitted medical patients. Whether significant asymptomatic hyperuricemia should be treated remains to be determined in further studies.
引用
收藏
页码:15 / 21
页数:7
相关论文
共 33 条
[1]   Uric acid and survival in chronic heart failure - Validation and application in metabolic, functional, and Hemodynamic staging [J].
Anker, SD ;
Doehner, W ;
Rauchhaus, M ;
Sharma, R ;
Francis, D ;
Knosalla, C ;
Davos, CH ;
Cicoira, M ;
Shamim, W ;
Kemp, M ;
Segal, R ;
Osterziel, KJ ;
Leyva, F ;
Hetzer, R ;
Ponikowski, P ;
Coats, AJS .
CIRCULATION, 2003, 107 (15) :1991-1997
[2]   When and why a water-soluble antioxidant becomes pro-oxidant during copper-induced low-density lipoprotein oxidation: a study using uric acid [J].
Bagnati, M ;
Perugini, C ;
Cau, C ;
Bordone, R ;
Albano, E ;
Bellomo, G .
BIOCHEMICAL JOURNAL, 1999, 340 :143-152
[3]   Xanthine oxicloreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications [J].
Berry, CE ;
Hare, JM .
JOURNAL OF PHYSIOLOGY-LONDON, 2004, 555 (03) :589-606
[4]  
BLACK HR, 2002, JAMA-J AM MED ASSOC, V288, P2981
[5]   Biomarkers in heart failure [J].
Braunwald, Eugene .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (20) :2148-2159
[6]   Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT) [J].
Brown, MJ ;
Palmer, CR ;
Castaigne, A ;
de Leeuw, PW ;
Mancia, G ;
Rosenthal, T ;
Ruilope, LM .
LANCET, 2000, 356 (9227) :366-372
[7]   Uric acid and the vasculature [J].
Corry, Dalila B. ;
Tuck, Michael L. .
CURRENT HYPERTENSION REPORTS, 2006, 8 (02) :116-119
[8]  
FANG J, 2003, JAMA-J AM MED ASSOC, V283, P2404
[9]   Uric acid and cardiovascular risk [J].
Feig, Daniel I. ;
Kang, Duk-Hee ;
Johnson, Richard J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (17) :1811-1821
[10]   Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP) [J].
Franse, LV ;
Pahor, M ;
Di Bari, M ;
Shorr, RI ;
Wan, JY ;
Somes, GW ;
Applegate, WB .
JOURNAL OF HYPERTENSION, 2000, 18 (08) :1149-1154